All Categories
Development at Creamino remains pleasing – start of additional production capacities initiated in August 2019 with first functional tests Investment phase at NITRALZ® completed within schedule and budget – commissioning – commissioning in progress
At the last Annual General Meeting on May 14, 2019, the shareholders of AlzChem Group AG resolved, among other things, to consolidate the issued shares at a ratio of 10 to 1. With this measure, the number of shares will be adjusted to a ratio commensurate with the size and value of the company and the stock exchange price per share will thereby be increased to a level customary on the capital market.
The Supervisory Board of AlzChem Group AG has decided to appoint Mr. Andreas Niedermaier (CFO) as the new CEO with effect from July 1, 2019, in view of the resignation of the current CEO Mr. Ulli Seibel as of December 31, 2019. In this function, Mr. Niedermaier will also be responsible for Investor Relations and Communications.
At today's Annual General Meeting of AlzChem Group AG, a vertically integrated specialty chemicals supplier with a leading market position in selected niche markets, the shareholders present honored the successful business development and corporate strategy and expressed their confidence in the Management Board and Supervisory Board.
Trostberg, April 3, 2019 – Ulli Seibel, CEO of AlzChem Group AG, informed the Supervisory Board today that he will no longer be available to the company for personal reasons after the expiration of his contract, which runs until December 31, 2019.
Ulli Seibel, CEO of AlzChem Group AG, informed the Supervisory Board today that he will leave the company on December 31, 2019 for personal reasons.
Sales in 2018 increase by 6.0% to 375.2 million euros EBITDA in 2018 rises by 8.1% to EUR 49.4 million Dividend proposal of EUR 0.09 for short fiscal year from July to December 2018 Forecast 2019: sales growth to EUR 389.9 to 398.9 million with stable EBITDA
With its creatine product LIVADUR®, AlzChem Group AG will be addressing end consumers directly for the first time as of March 2019. The target audience consists of active people aged 55 and over who want to prevent the age-related decline in muscle strength and thus maintain their high quality of life and fitness. The dietary supplement is based on the already very successful product Creapure®, the only creatine product manufactured in Germany that is supplied to the dietary supplement industry specifically for sports nutrition.